"We are paving the way for the development of mucin-based biopharmaceuticals targeting the ophthalmology market."
- Jan Holgersson, MD, PhD
Recopharma is a biotechnology company, founded in 2004. The company is based in Gothenburg, Sweden, at the Biotech Center.
Recopharma carries out activities in the field of ophthalmology, developing potential products for treatment of eye diseases. The Company has developed a unique technology, with many potential applications, that uses mucins, which naturally occur in lacrimal fluid, where they protect, lubricate and help keep the tear film intact.
For the treatment of dry eyes, which often affect the elderly and people wearing contact lenses, the goal is to provide a natural alternative to the currently available ocular lubricants and tear substitutes. The clinical phase for this product is expected to begin during 2014.For viral conjunctivitis there are currently no drugs available on the market. The viruses bind to specific sugar structures on the ocular epithelium. Recopharma is developing a mucin-like protein for the inhibition of this type of viral eye infection. The recombinant mucin can be made to carry more copies of the sugars and thus prevent the virus from binding to the cells of the eye.
Arvid Wallgrens backe 20, 413 46 Göteborg, Sweden
Phone: +46-70-685 9872